2017 No. 631
Dangerous Drugs, England And Wales
Dangerous Drugs, Scotland

The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017

Made
Coming into force
To be laid before Parliament
The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 19711.

In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

Citation, commencement and extent

1.

(1)

These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.

(2)

These Regulations extend to England and Wales and Scotland.

Amendment of the Misuse of Drugs Regulations 2001

2.

The Misuse of Drugs Regulations 20012 are amended as follows.

3.

In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16 , 18, 19, 20, 23, 26 and 27)—

(a)

before “Bufotenine” insert—

  • “Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

  • N-Benzyl-ethylphenidate

  • Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;

(b)

after “Cathinone” insert—

  • “4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(c)

after “Concentrate of poppy-straw” insert—

  • “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • 3,4-Dichloroethylphenidate

  • 3,4-Dichloromethylphenidate (3,4-DCMP)

  • Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(d)

after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—

  • “Ethylnaphthidate

  • Ethylphenidate”;

(e)

after “Eticyclidine” insert—

  • “Etizolam”;

(f)

after “Etryptamine” insert—

  • “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

  • 4-Fluoroethylphenidate

  • 4-Fluoromethylphenidate

  • Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(g)

after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol” insert—

  • “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Isopropylphenidate (IPP or IPPD)”;

(h)

after “Lysergide and other N-alkyl derivatives of lysergamide” insert—

  • “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(i)

after “Methcathinone” insert—

  • “4-Methylmethylphenidate

  • Methylmorphenate

  • Methylnaphthidate (HDMP-28)

  • Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)

  • Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

  • Propylphenidate”;

(j)

after “Psilocin” insert—

  • “Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(k)

after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—

  • “3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”.

Sarah Newton
Parliamentary Under Secretary of State
Home Office
EXPLANATORY NOTE
(This note is not part of the Regulations)

These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the Regulations”). The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.

Regulation 3 adds a synthetic opioid (known as U-47,700), several methylphenidate related materials and a number of designer benzodiazepines to Schedule 1 to the Regulations. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.

An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.